Preprint Article Version 1 This version is not peer-reviewed

Circulating microRNAs as Biomarkers for the Differential Diagnosis of Lung Cancer and Tuberculosis

Version 1 : Received: 31 October 2024 / Approved: 31 October 2024 / Online: 1 November 2024 (10:17:39 CET)

How to cite: Ashirbekov, Y.; Khamitova, N.; Satken, K.; Abaildayev, A.; Pinskiy, I.; Yeleussizov, A.; Yegenova, L.; Kairanbayeva, A.; Kadirshe, D.; Utegenova, G.; Jainakbayev, N.; Sharipov, K. Circulating microRNAs as Biomarkers for the Differential Diagnosis of Lung Cancer and Tuberculosis. Preprints 2024, 2024102595. https://doi.org/10.20944/preprints202410.2595.v1 Ashirbekov, Y.; Khamitova, N.; Satken, K.; Abaildayev, A.; Pinskiy, I.; Yeleussizov, A.; Yegenova, L.; Kairanbayeva, A.; Kadirshe, D.; Utegenova, G.; Jainakbayev, N.; Sharipov, K. Circulating microRNAs as Biomarkers for the Differential Diagnosis of Lung Cancer and Tuberculosis. Preprints 2024, 2024102595. https://doi.org/10.20944/preprints202410.2595.v1

Abstract

Background/Objectives: The differential diagnosis of tuberculosis (TB) and lung cancer (LC) is often challenging due to similar clinicopathological presentations when bacterial shedding is negative, which can lead to delays in treatment. In this study, we tested the potential of plasma-circulating microRNAs (miRNAs) for the early and differential diagnosis of TB and LC. Methods: We conducted a two-phase study: profiling 188 miRNAs in pooled plasma samples and validating 14 selected miRNAs in individual plasma samples from 68 LC patients, 38 pulmonary TB patients, and 41 healthy controls. Results: Twelve miRNAs were significantly elevated in LC patients compared to controls and TB patients, while two miRNAs were significantly elevated in TB patients compared to controls. ROC analysis demonstrated that miR-130b-3p, miR-1-3p, miR-423-5p, and miR-200a-3p had good discriminatory ability to distinguish LC patients (including those with stage I tumours) from healthy individuals and miR-130b-3p, miR-423-5p, miR-15b-5p, and miR-18b-5p effectively distinguished LC patients (including those with stage I tumours) from TB patients. Additionally, miR-18b-5p showed good discriminatory ability between SCLC and NSCLC patients. Conclusions: Circulating miRNAs hold strong potential for the early detection of LC and for distinguishing LC from TB.

Keywords

lung cancer; tuberculosis; differential diagnosis; microRNA

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.